NICE - Endorsed Technology Appraisals 2016/2017
It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.
Technology Appraisals Endorsement Process
The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland. The new arrangements are detailed in following circulars, which is effective from 18th December 2013;
NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13
For information, details of the previous arrangement can be found on the following circular;
NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11
2016/2017
The following technology appraisals have been endorsed during 2016/17. Information on technology appraisals endorsed in previous years can be found on the homepage.
Fully Endorsed
March 2017
- NICE TA 432 - Everolimus for advanced renal cell carcinoma after previous treatment
- This guidance updates and replaces NICE Technology Appraisal TA219, which was endorsed by the DoH in December 2011.
- NICE TA 433 – Apremilast for treating active psoriatic arthritis
- This guidance updates and replaces NICE Technology Appraisal TA372, which was endorsed by the DoH in January 2016.
February 2017
- NICE TA 427 - Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (review of TA338)
- This guidance updates and replaces NICE Technology Appraisal TA338, which was endorsed by the DoH in May 2015.
- NICE TA 428 - Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
- NICE TA 429 - Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation.
- NICE TA 430 - Sofosbuvir-Velpatasvir for Treating Chronic Hepatitis C.
- NICE TA 431 - Mepolizumab for Treating Severe Refractory Eosinophilic Asthma. Note this guidance has been updated and replaced by TA671 - Mepolizumab for treating severe eosinophilic asthma, which was endorsed by the DoH in March 2021.
January 2017
- NICE TA 421 - Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
- This guidance updates and replaces NICE Technology Appraisal TA295, which was endorsed by the DoH in September 2013.
- NICE TA 422 - Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
- This guidance updates and replaces NICE Technology Appraisal TA296, which was endorsed by the DoH in October 2013.
- NICE TA 423 - Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
- This guidance updates and replaces NICE Technology Appraisal TA250, which was endorsed by the DoH in May 2012.
- NICE TA 424 - Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
- NICE TA 425 - Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
- This guidance updates and replaces NICE Technology Appraisal TA241, which was endorsed by the DoH in February 2012 and partially updates TA70, which was endorsed by the DoH in March 2012.
- NICE TA 426 - Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
- This guidance updates and replaces NICE Technology Appraisal TA251, which was endorsed by the DoH in May 2012 and partially updates TA70, which was endorsed by the DoH in March 2012.
- NICE TA 427 - Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (review of TA338)
- This guidance updates and replaces NICE Technology Appraisal TA338, which was endorsed by the DoH in May 2015.
December 2016
- NICE TA 417 - Nivolumab for treated or metastatic renal cell carcinoma
- NICE TA 418 - Dapagliflozin in triple therapy for treating type 2 diabetes
- This guidance updates and replaces recommendation 1.3 of NICE Technology Appraisal TA288, which was endorsed by the DoH in July 2013.
- NICE TA 419 - Apremilast for treating moderate to severe plaque psoriasis
- This guidance updates and replaces NICE Technology Appraisal TA368, which was endorsed by the DoH in December 2015.
- NICE TA 420 - Ticagrelor for secondary prevention of atherothrombotic events after myocardial infarction
November 2016
- NICE TA 413 - Elbasvir-grazoprevir for treating chronic hepatitis C
- NICE TA 414 - Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
- NICE TA 415 - Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF inhibitor
October 2016
- NICE TA 406 - Crizotinib for untreated anaplastic lymphoma kinase-positive non-small-cell lung cancer
- NICE TA 407 - Secukinumab for treating ankylosing spondylitis after inadequate response to non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
- NICE TA 408 - Pegaspargase for treating acute lymphoblastic leukaemia
- NICE TA 409 - Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
- NICE TA 410 - Talimogene laherparepvec for treating metastatic melanoma
- NICE TA 411 - Necitumumab for untreated advanced or metastatic, squamous non-small-cell lung cancer
- NICE TA 412 - Radium-223 dichloride for treating metastatic hormone relapsed prostate cancer with bone metastases (Review of TA376)
- This guidance updates and replaces TA376, which was endorsed by the DoH in February 2016.
September 2016
- NICE TA 401 - Bosutinib for previously treated chronic myeloid leukaemia
- This guidance updates and replaces TA 299, which was endorsed by the DoH in December 2013.
- NICE TA 402 - Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer
- This guidance updates and replaces TA 309, which was endorsed by the DoH in May 2014.
- NICE TA 403 - Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
- NICE TA 404 - Degarelix for treating advanced hormone-dependent prostate cancer
- NICE TA 405 - Trifluridine–tipiracil for previously treated metastatic colorectal cancer
August 2016
- NICE TA 398 - Lumacaftor–Ivacaftor for treating cystic fibrosis homozygous for the F508del mutation Note this guidance has been updated and replaced by TA988 - Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis, endorsed by the DoH in August 2024
- NICE TA 399 - Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
- NICE TA 400 - Nivolumab in combination with ipilimumab for treating advanced melanoma
July 2016
- NICE TA 392 - Adalimumab for treating moderate to severe hidradenitis suppurativa
- NICE TA 393 - Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
- NICE TA 394 - Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
- NICE TA 395 - Ceritinib for previously treated anaplastic lymphoma kinase-positive non-small-cell lung cancer
- NICE TA 396 - Trametinib in combination with dabrafenib for treating advanced (unresectable or metastatic) melanoma
- NICE TA 397 - Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus
‘Note this guidance has been updated and replaced by TA752 - Belimumab for treating active autoantibody-positive systemic lupus erythematosus, which was endorsed by the DoH in January 2022’.
June 2016
- NICE TA 387 - Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
- NICE TA 390 – Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
- NICE TA 391 – Cabazitaxel for hormone relapsed metastatic prostate cancer treated with docetaxel
- This guidance updates and replaces TA 255, which was endorsed by the DoH in May 2012.
May 2016
- NICE TA 386 - Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
- NICE TA 23 - Temozolomide for the treatment of recurrent malignant glioma (brain cancer)
- NICE TA 388 - Sacubitril valsartan for treating heart failure with systolic dysfunction
- NICE TA 389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
This guidance updates and replaces TA 222, which was endorsed by the DoH in November 2011.
- NICE TA 98 - Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents
- This guidance has been updated and replaced by NICE Clinical Guideline NG87 - Attention deficit hyperactivity disorder: diagnosis and management, which was endorsed by the DoH in May 2018